RECOVER/ARVIN-GOODS
Arvin Goods, the Seattle-based responsible apparel brand, has announced the release of its latest sock collection, crafted from Recover™ recycled cotton fiber. Since launching in 2019, the company has been at the forefront of sustainable fashion and is one of the few brands in the market utilizing recycled materials for its entire collection.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215745837/en/
(Photo: Arvin Goods)
The latest launch features crew socks made from 79% recycled materials, including 43% recycled polyester and 36% Recover recycled cotton fiber. Recover’s proprietary recycled fiber is one of the lowest-impact fibers available in the market, significantly reducing the carbon and water footprint of the apparel supply chain. Manufacturing just one pair of Arvin Goods socks made with 36% Recover fiber saves up to 18 gallons of water compared to a pair made with conventional cotton.
Boris Mercier, SVP Marketing at Recover, said, “Our ongoing work with Arvin Goods was born out of a shared belief in the importance of circular fashion that never sacrifices quality, feel, or style. As the ingredient brand of reference in recycled cotton, we aim to educate consumers to make more conscious choices and accelerate the adoption of sustainable initiatives within the casual wear segment.”
For each pair of socks, responsibility is the core of Arvin’s approach to the design, manufacturing, and distribution. As well as using low-impact impact recycled materials, responsibility was also prioritized in the value chain. Thanks to Recover’s strategic partnership with Ferre Yarns, based locally in Alicante, Spain the impact of transportation was also minimized.
Dustin Winegardner, Managing Partner at Arvin Goods, commented, “We have been working with Recover™, and the Ferre family of yarns since the beginning of Arvin Goods. Making it official like this and stamping the R on our packaging is an exciting step for our brand. Being able to source materials in Spain, and manufacture nearby in Portugal moves us further in our mission to deliver The Cleanest Basics on the Planet.”
Paqui Ferre, Sales and Marketing Director at Ferre, also commented, “Ferre has been working with Arvin Goods since the beginning of its history. In a clear commitment to sustainability, Arvin makes products using our most iconic yarn, FBlue. Consistent with our brand vision, FBLUE 100% recycled yarns deliver the perfect combination of circularity, performance, and color accuracy. A blend with Recover recycled cotton that answers the global call for sustainably sourced yarns while providing inspiring colors for Arvin Goods products.”
The new collection not only exemplifies Arvin Goods' sustainable ethos but also provides customers with a stylish and comfortable choice for everyday wear. The brand continues to set a new standard for low-impact fashion, encouraging consumers to make conscious choices that positively impact the planet.
The Arvin Goods recycled fiber collection starts at $12 USD and is available to purchase through their website.
Find out more about the collaboration here.
About Arvin Goods
Established in 2019 Arvin Goods has set out to help clean up a dirty industry. By utilizing recycled base materials and minimizing the movement of materials in manufacturing they are reducing the impact of one of the world's most consumed categories. Basics.
Arvin Goods produces comfortable on-trend products, that also happen to be the lowest-impact socks in the marketplace. Arvin Goods is based in Seattle, Washington USA.
About Recover™
Recover™ is a leading materials science company and global producer of low-impact, high-quality recycled cotton fiber and cotton fiber blends at scale. Its premium, environmentally friendly, and cost-competitive products are created in partnership with the supply chain for global retailers and brands, offering a sustainable solution to achieve circular fashion for all. As a fourth-generation, family-owned company, and backed by recent investment from STORY3 Capital and Goldman Sachs, Recover™ is on a mission to scale its proprietary technology to make a lasting positive impact on the environment and partner with brands/retailers and other change-makers to meet the industry’s sustainability targets.
About Ferre
Ferre is a fourth-generation family business with a history of more than 75 years innovating the manufacture of high-quality recycled yarns. Our open-end spin factory is based in Banyeres de Mariola (Alicante), Spain and the company, founded in 1947, has been innovating the cotton recycled spinning process ever since.
We work every day to improve our products and help our customers to maximize the full potential of our low-impact yarns, always guided for the commitment of making more with less. Ferre yarns stand out for their quality and low-impact products, bringing accurate and beautiful colours to the sustainable fashion value chain.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215745837/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
